Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

New study puts focus on early symptoms of Huntington’s disease

Åsa Petersén and Sanaz Gabery sitting in stairwell
Åsa Petersén and Sanaz Gabery (Photo: Agata Garpenlind)

Psychiatric and cognitive symptoms emerge at an early stage in Huntington’s disease. However, research so far has mainly focused on movement impairment, a symptom associated with the more advanced stages of the disease. A new study from Lund University in Sweden now shows that the emotional brain - the limbic system - is affected earlier in the course of the disease, and should therefore be given more attention in the development of new treatments.

Huntington’s is a fatal illness with no treatment to slow its course. The new research findings provide knowledge about where the early changes take place in the brain. This is important for the development of new treatments which, according to the researchers, should target the earliest disease-related changes.

“Our results show that the emotional brain is affected at an early stage, and that this can contribute to the development of psychiatric and cognitive symptoms, which are the most difficult for the patients and their relatives. It is not only nerve cells that are affected, but also other cells, oligodendrocytes, which enable communication between different parts of the brain, that are affected early in the course of the disease”, explains Åsa Petersén, professor of neuroscience at Lunds University and senior consultant in psychiatry at the Huntington Centre in Lund.

Huntington’s disease is caused by a known genetic mutation that results in the production of a protein known as mutant huntingtin in all the cells of the body. However, only certain cells are very sensitive to the protein mutation and these are in specific areas of the brain.

“It is still a mystery why certain cells are sensitive to the protein mutation and why the disease starts to break out at a certain time, even though it was there all along. However, our study shows for the first time that changes in the oligodendrocytes in the emotional brain are expressed in the brains of individuals suffering from Huntington’s disease”, says researcher and first author of the study, Sanaz Gabery.

The researchers believe that previous research focused too much on the typical movement impairments associated with Huntington’s disease and the link to effects on the movement control centre.

“The emotional brain and cells other than just nerve cells are affected by the development of Huntington’s disease. The nerve-fibre system in the emotional brain is already reduced before the typical movement impairments emerge. The changes consist of damage to myelin, i.e. the insulation system in the white matter of the brain, which is important for information transfer, and an effect on genes that are important for oligodendrocytes’ identity and function”, explains Åsa Petersén.

“Today, many researchers are focused on reducing the levels, and thereby the effect, of the disease-inducing mutant huntingtin in the nerves cells and in the brain’s movement control centre. But our findings indicate that there is also a need to examine the white matter in the emotional brain. Why are oligodendrocytes sensitive to mutant huntingtin? Is it possible to slow down Huntington’s disease by affecting the changes that we have identified?”

Publication:

Contact:

Åsa Petersén, professor of neuroscience at Lund University and senior consultant in psychiatry at the Huntington Disease Centre in Lund, Psychiatry Skåne
+46 709422930
asa [dot] petersen [at] med [dot] lu [dot] se

Funding

Sanaz Gabery is a postdoc funded by the Swedish Brain Foundation. Åsa Petersén was named as the 2020 Wallenberg Clinical Scholar by the Knut and Alice Wallenberg Foundation. The study is also funded by support from the Swedish Research Council, ALF/Region Skåne, Neuro, the Faculty of Medicine at Lund University and through other support via the international collaboration.

About the study

The study is a successful multi-year collaboration between Åsa Petersén's research team and researchers in Australia with the LU Faculty of Medicine’s new honorary doctor Glenda Halliday, University of Sydney; Professor Nellie Georgiou-Karistianis and her team at Monash University, Melbourne; Professor Catriona McLean, Alfred Hospital, Melbourne, as well as Associate Professor Mahmoud Pouladi and his team at the National University of Singapore and the University of British Columbia, Vancouver. 

Unique post-mortem human tissue has been received from the Sydney Brain Bank, Neuroscience Research Australia, the New South Wales (NSW) Brain Tissue Resource Centre at the University of Sydney, and the Victorian Brain Bank, Melbourne.